Compare Enveric Biosciences Inc (ENVB) vs General Mills, Inc. (GIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs General Mills, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.38 (market cap $5.32M), while General Mills, Inc. trades at $39.05 (market cap $19.46B). The key difference: General Mills, Inc. is far larger — about 3657.9× Enveric Biosciences Inc's market cap, and General Mills, Inc. pays a 6.69% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | GIS | |
|---|---|---|
Market Cap | $5.32M | $19.46B |
Sector | Health | Consumer Staples |
52-Week High | $17.40 | $51.27 |
52-Week Low | $1.28 | $32.17 |
Enterprise Value | $408.82K | $32.95B |
Dividend Yield | — | 6.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
General Mills (GIS) trades at $38.95, up 6.83% in the last session, with a bullish technical signal from moving averages. The stock shows mixed earnings performance, beating estimates in Q3 2025 and Q2 2026 but missing in Q4 2025. Revenue declined to $19.49B in 2025, with net income margin turning negative at -0.48% for 2026. Recent news highlights partnerships in regenerative agriculture and cost-saving initiatives targeting $3 billion by 2030 to support margins amid soft demand.
The outlook is cautious; while valuation appears attractive with a P/E of 9.23, weak sales and profit pressure pose risks. Analyst consensus is mixed with 22.22% buy ratings, but the average price target of $36.14 suggests limited upside. Key risks include competitive pressures and macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
